Maria-jose Calasanz

Pamplona, NC 00489, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Journal: Blood
Published: December 04, 2025

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

Journal: HemaSphere
Published: December 20, 2024

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Journal: Clinical lymphoma, myeloma & leukemia
Published: October 22, 2024

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.

Journal: Blood cancer discovery
Published: October 01, 2024

RASping myeloma genomics.

RASping myeloma genomics.

Journal: Blood
Published: July 11, 2024

Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients.

Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients.

Journal: HemaSphere
Published: April 24, 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Journal: Haematologica
Published: April 23, 2024

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.

Journal: Blood neoplasia
Published: February 20, 2024

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Journal: Blood
Published: August 03, 2023

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Journal: Haematologica
Published: May 05, 2023

Highs and lows of t(4;14) in multiple myeloma.

Highs and lows of t(4;14) in multiple myeloma.

Journal: Blood
Published: March 30, 2023

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Journal: British journal of haematology
Published: January 20, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026